The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...
Shares in iTeos Therapeutics surged after the company said it would wind down operations. The stock was up 27% at $10.87 in premarket trading. Shares were already up 11% year-to-date when the market ...
Moved iTeos Therapeutics to a Hold rating after the failure of the belrestotug + dostarlimab program in NSCLC, plus the ending of the GSK collaboration agreement. Despite the belrestotug setback, ...
WATERTOWN, Mass. and GOSSELIES, Belgium, May 13, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...
iTeos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 Phase 2 study on Tuesday. The trial sponsored by GSK Plc (NYSE:GSK) assessed ...
All belrestotug-containing cohorts are ending, and any new enrollment in the ongoing GALAXIES Lung-301 Phase 3 trial is ending. GSK is communicating with investigators, institutional review boards, ...
(Alliance News) - GSK PLC on Tuesday said it is ending the development programme for monoclonal antibody belrestotug. Shares in GSK were down 1.3% to 1,381.00 pence in London on Tuesday afternoon. The ...
GSK plc (LSE/NYSE:LON:GSK), in partnership with iTeos Therapeutics, Inc., has announced the termination of the development program for belrestotug, an investigational anti-TIGIT monoclonal antibody.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback